Genotypic analysis of the V3 region of HIV from virologic nonresponders to maraviroc-containing regimens reveals distinct patterns of failure

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 12, 2013, Pages 6122-6130

  Swenson, Luke C ^a   Chui, Celia K S ^a   Brumme, Chanson J ^a   Chan, Dennison ^a   Woods, Conan K ^a   Mo, Theresa ^a   Dong, Winnie ^a   Chapman, Doug ^b   Lewis, Marilyn ^b   Demarest, James F ^b   James, Ian ^b   Portsmouth, Simon ^b   Goodrich, James ^d   Heera, Jayvant ^c   Valdez, Hernan ^b   Harrigan, P Richard ^a  

^a BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

^b PFIZER INC   (United States)

^c PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^d VIIV HEALTHCARE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CHEMOKINE RECEPTOR CXCR4; MARAVIROC; UNCLASSIFIED DRUG; VIRUS PROTEIN V; VIRUS PROTEIN V3; CCR5 PROTEIN, HUMAN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CXCR4 PROTEIN, HUMAN; CYCLOHEXANE DERIVATIVE; GLYCOPROTEIN GP 120; HIV ENVELOPE PROTEIN GP120 (305-321); HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; PEPTIDE FRAGMENT; TRIAZOLE DERIVATIVE;

ADULT; AGED; ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DRUG EFFICACY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; GENE SEQUENCE; GENETIC ALGORITHM; GENETIC ANALYSIS; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; SCREENING TEST; SENSITIVITY AND SPECIFICITY; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VIRAL TROPISM; VIROLOGY; VIRUS ENTRY; VIRUS ENVELOPE; VIRUS LOAD; VIRUS STRAIN; ADOLESCENT; CHEMISTRY; DRUG EFFECTS; GENE EXPRESSION; GENETICS; HIGH THROUGHPUT SEQUENCING; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; METABOLISM; MIDDLE AGED; TREATMENT FAILURE;

ADOLESCENT; ADULT; AGED; CCR5 RECEPTOR ANTAGONISTS; CYCLOHEXANES; FEMALE; GENE EXPRESSION; GENOTYPE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HIV ENVELOPE PROTEIN GP120; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; RECEPTORS, CCR5; RECEPTORS, CXCR4; TREATMENT FAILURE; TRIAZOLES; VIRAL TROPISM;

EID: 84887470292     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01534-13     Document Type: Article

References (37)

1. Gulick RM, Lalezari J, Goodrich J, Clumeck N, DeJesus E, Horban A, Nadler J, Clotet B, Karlsson A, Wohlfeiler M, Montana JB, McHale M, Sullivan J, Ridgway C, Felstead S, Dunne MW, van der Ryst E, Mayer H. 2008. Maraviroc for previously treated patients with R5 HIV-1 infection. N. Engl. J. Med. 359:1429-1441.
2. Saag M, Goodrich J, Fätkenheuer G, Clotet B, Clumeck N, Sullivan J, Westby M, van der Ryst E, Mayer H. 2009. A double-blind, placebocontrolled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1. J. Infect. Dis. 199:1638-1647.
3. Fätkenheuer G, Nelson M, Lazzarin A, Konourina I, Hoepelman AIM, Lampiris H, Hirschel B, Tebas P, Raffi F, Trottier B, Bellos N, Saag M, Cooper DA, Westby M, Tawadrous M, Sullivan JF, Ridgway C, Dunne MW, Felstead S, Mayer H, van der Ryst E. 2008. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N. Engl. J. Med. 359: 1442-1455.
4. Wilkin TJ, Goetz MB, Leduc R, Skowron G, Su Z, Chan ES, Heera J, Chapman D, Spritzler J, Reeves JD, Gulick RM, Coakley E. 2011. Reanalysis of coreceptor tropism in HIV-1-infected adults using a phenotypic assay with enhanced sensitivity. Clin. Infect. Dis. 52:925-928.
5. Cooper D, Heera J, Goodrich J, Tawadrous M, Saag M, Dejesus E, Clumeck N, Walmsley S, Ting N, Coakley E, Reeves JD, Reyes-Teran G, Westby M, Van Der Ryst E, Ive P, Mohapi L, Mingrone H, Horban A, Hackman F, Sullivan J, Mayer H. 2010. Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral- naive subjects with CCR5-tropic HIV-1 infection. J. Infect. Dis. 201:803-813.
6. McGovern RA, Thielen A, Portsmouth S, Mo T, Dong W, Woods CK, Zhong X, Brumme CJ, Chapman D, Lewis M, James I, Heera J, Valdez H, Harrigan PR. 2012. Population-based sequencing of the V3-loop can predict the virological response to maraviroc in treatment-naive patients of the MERIT trial. J. Acquir. Immune Defic. Syndr. 61:279-286.
7. Swenson LC, Mo T, Dong WWY, Zhong X, Woods CK, Thielen A, Jensen M, Knapp DJHF, Chapman D, Portsmouth S, Lewis M, James I, Heera J, Valdez H, Harrigan PR. 2011. Deep V3 sequencing for HIV type 1 tropism in treatment-naive patients: a reanalysis of the MERIT trial of maraviroc. Clin. Infect. Dis. 53:732-742.
8. Swenson LC, Mo T, Dong WWY, Zhong X, Woods CK, Jensen MA, Thielen A, Chapman D, Lewis M, James I, Heera J, Valdez H, Harrigan PR. 2011. Deep sequencing to infer HIV-1 co-receptor usage: application to three clinical trials of maraviroc in treatment-experienced patients. J. Infect. Dis. 203:237-245.
9. McGovern RA, Thielen A, Mo T, Dong W, Woods CK, Chapman D, Lewis M, James I, Heera J, Valdez H, Harrigan PR. 2010. Populationbased V3 genotypic tropism assay: a retrospective analysis using screening samples from the A4001029 and MOTIVATE studies. AIDS 24:2517-2525.
10. Kagan RM, Johnson EP, Siaw M, Biswas P, Chapman DS, Su Z, Platt JL, Pesano RL. 2012. A genotypic test for HIV-1 tropism combining Sanger sequencing with ultradeep sequencing predicts virologic response in treatment- experienced patients. PLoS One 7:e46334. doi:10.1371/journal .pone.0046334.
11. Swenson LC, Boehme R, Thielen A, McGovern RA, Harrigan PR. 2010. Genotypic determination of HIV-1 tropism in the clinical setting. HIV Ther. 4:293-303.
12. Sing T, Low AJ, Beerenwinkel N, Sander O, Cheung PK, Domingues FS, Büch J, Däumer M, Kaiser R, Lengauer T, Harrigan PR. 2007. Predicting HIV coreceptor usage on the basis of genetic and clinical covariates. Antivir. Ther. 12:1097-1106.
13. Swenson LC, Däumer M, Paredes R. 2012. Next-generation sequencing to assess HIV tropism. Curr. Opin. HIV AIDS 7:478-485.
14. Raymond S, Saliou A, Nicot F, Delobel P, Dubois M, Cazabat M, Sandres-Sauné K, Marchou B, Massip P, Izopet J. 2011. Frequency of CXCR4-using viruses in primary HIV-1 infections using ultra-deep pyrosequencing. AIDS 25:1668-1673.
15. Archer J, Weber J, Henry K, Winner D, Gibson R, Lee L, Paxinos E, Arts EJ, Robertson DL, Mimms L, Quinones-Mateu ME. 2012. Use of four next-generation sequencing platforms to determine HIV-1 coreceptor tropism. PLoS One 7:e49602. doi:10.1371/journal.pone.0049602.
16. Archer J, Braverman MS, Taillon BE, Desany B, James I, Harrigan PR, Lewis M, Robertson DL. 2009. Detection of low-frequency pretherapy chemokine (CXC motif) receptor 4 (CXCR4)-using HIV-1 with ultradeep pyrosequencing. AIDS 23:1209-1218.
17. Westby M, Lewis M, Whitcomb J, Youle M, Pozniak AL, James IT, Jenkins TM, Perros M, Van Der Ryst E. 2006. Emergence of CXCR4- using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir. J. Virol. 80:4909-4920.
18. Tilton JC, Wilen CB, Didigu CA, Sinha R, Harrison JE, Agrawal-Gamse C, Henning EA, Bushman FD, Martin JN, Deeks SG, Doms RW. 2010. A maraviroc-resistant HIV-1 with narrow cross-resistance to other CCR5 antagonists depends on both N-terminal and extracellular loop domains of drug-bound CCR5. J. Virol. 84:10863-10876.
19. Schapiro JM, Boucher CA, Kuritzkes DR, van de Vijver DA, Llibre JM, Lewis M, Simpson P, Delogne C, McFadyen L, Chapman D, Perros M, Valdez H, van der Ryst E, Westby M. 2011. Baseline CD4- T-cell counts and weighted background susceptibility scores strongly predict response to maraviroc regimens in treatment-experienced patients. Antivir. Ther. 16:395-404.
20. McGovern RA, Symons J, Poon AFY, Harrigan PR, van Lelyveld SFL, Hoepelman AIM, van Ham PM, Dong W, Wensing AMJ, Nijhuis M. 2013. Maraviroc treatment in non-R5-HIV-1-infected patients results in the selection of extreme CXCR4-using variants with limited effect on the total viral setpoint. J. Antimicrob. Chemother. 68:2007-2014.
21. Tsibris AMN, Korber B, Arnaout R, Russ C, Lo C-C, Leitner T, Gaschen B, Theiler J, Paredes R, Su Z, Hughes MD, Gulick RM, Greaves W, Coakley E, Flexner C, Nusbaum C, Kuritzkes DR. 2009. Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo. PLoS One 4:e5683. doi:10 .1371/journal.pone.0005683.
22. Roche M, Salimi H, Duncan R, Wilkinson BL, Chikere K, Moore MS, Webb NE, Zappi H, Sterjovski J, Flynn JK, Ellett A, Gray LR, Lee B, Jubb B, Westby M, Ramsland PA, Lewin SR, Payne RJ, Churchill MJ, Gorry PR. 2013. A common mechanism of clinical HIV-1 resistance to the CCR5 antagonist maraviroc despite divergent resistance levels and lack of common gp120 resistance mutations. Retrovirology 10:43. doi:10.1186/1742-4690-10-43.
23. McGovern RA, Dong W, Mo T, Woods C, Zhong X, Thielen A, Jensen M, Heera J, Ellery S, Lewis M, James I, Biswas P, Chapman D, Valdez H, Harrigan R. 2009. Optimization of clinically relevant cutpoints for the determination of HIV co-receptor usage to predict maraviroc responses in treatment experienced (TE) patients using population V3 genotyping, poster PE3.4/8. In Abstr. 12th Eur. AIDS Conf. European AIDS Clinical Society, Cologne, Germany.
24. Swenson LC, Dong W, Mo T, Woods C, Zhong X, Thielen A, Jensen M, Biswas P, Ellery S, Lewis M, James I, Chapman D, Valdez H, Harrigan R. 2009. "Deep" sequencing to identify treatment-experienced patients who respond to maraviroc (MVC), poster PE3.3/2. In Abstr. 12th Eur. AIDS Conf. European AIDS Clinical Society, Cologne, Germany.
25. Lalezari J, Goodrich J, DeJesus E, Lampiris H, Gulick R, Saag M, Ridgway C, McHale M, van der Ryst E, Mayer H. 2007. Efficacy and safety of maraviroc plus optimized background therapy in viremic, ARTexperienced patients infected with CCR5-tropic HIV-1: 24-week results of phase 2b/3 studies, abstr 104bLB. In Abstr. 14th Conf. Retroviruses Opportun. Infect., Los Angeles, CA.
26. Resch W, Hoffman N, Swanstrom R. 2001. Improved success of phenotype prediction of the human immunodeficiency virus type 1 from envelope variable loop 3 sequence using neural networks. Virology 288:51-62.
27. Obermeier M, Symons J, Wensing AMJ. 2012. HIV population genotypic tropism testing and its clinical significance. Curr. Opin. HIV AIDS 7:470-477.
28. Low AJ, Dong W, Chan D, Sing T, Swanstrom R, Jensen M, Pillai S, Good B, Harrigan PR. 2007. Current V3 genotyping algorithms are inadequate for predicting X4 co-receptor usage in clinical isolates. AIDS 21:F17-F24. doi:10.1097/QAD.0b013e3282ef81ea.
29. De Mendoza C, Van Baelen K, Poveda E, Rondelez E, Zahonero N, Stuyver L, Garrido C, Villacian J, Soriano V. 2008. Performance of a population-based HIV-1 tropism phenotypic assay and correlation with V3 genotypic prediction tools in recent HIV-1 seroconverters. J. Acquir. Immune Defic. Syndr. 48:241-244.
30. Skrabal K, Low AJ, Dong W, Sing T, Cheung PK, Mammano F, Harrigan PR. 2007. Determining human immunodeficiency virus coreceptor use in a clinical setting: degree of correlation between two phenotypic assays and a bioinformatic model. J. Clin. Microbiol. 45:279-284.
31. Demarest JF, Amrine-Madsen H, Irlbeck DM, Kitrinos KM. 2009. Virologic failure in first-linehumanimmunodeficiency virus therapy with aCCR5 entry inhibitor, aplaviroc, plus a fixed-dose combination of lamivudinezidovudine: nucleoside reverse transcriptase inhibitor resistance regardless of envelope tropism. Antimicrob. Agents Chemother. 53:1116-1123.
32. Brumme ZL, Dong WWY, Yip B, Wynhoven B, Hoffman NG, Swanstrom R, Jensen MA, Mullins JI, Hogg RS, Montaner JSG, Harrigan PR. 2004. Clinical and immunological impact of HIV envelope V3 sequence variation after starting initial triple antiretroviral therapy. AIDS 18:F1. doi:10.1097/00002030- 200403050-00001.
33. Brumme ZL, Goodrich J, Mayer HB, Brumme CJ, Henrick BM, Wynhoven B, Asselin JJ, Cheung PK, Hogg RS, Montaner JSG, Harrigan PR. 2005. Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals. J. Infect. Dis. 192: 466-474.
34. Westby M, Smith-Burchnell C, Mori J, Lewis M, Mosley M, Stockdale M, Dorr P, Ciaramella G, Perros M. 2007. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J. Virol. 81:2359-2371.
35. Moore JP, Kuritzkes DR. 2009. A pièce de resistance: how HIV-1 escapes small molecule CCR5 inhibitors. Curr. Opin. HIV AIDS 4:118-124.
36. Delobel P, Cazabat M, Saliou A, Loiseau C, Coassin L, Raymond S, Requena M, Marchou B, Massip P, Izopet J. 21 June 2013. Primary resistance of CCR5-tropic HIV-1 to maraviroc cannot be predicted by the V3 sequence. J. Antimicrob. Chemother. [Epub ahead of print.]. doi:10 .1093/jac/dkt249.
37. McNicholas P, Vilchez RA, Greaves W, Kumar S, Onyebuchi C, Black T, Strizki JM. 2012. Detection of HIV-1 CXCR4 tropism and resistance in treatment experienced subjects receiving CCR5 antagonist-vicriviroc. J. Clin. Virol. 55:134-139.